Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
Leukemia. 2024 Aug;38(8):1818-1821. doi: 10.1038/s41375-024-02317-4. Epub 2024 Jul 24.
Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein.
Biomedicines, 12(7), 1573. https://doi.org/10.3390/biomedicines12071573
Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia.
Molecular therapy. Nucleic acids, 35(2), 102202. https://doi.org/10.1016/j.omtn.2024.102202
A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation
Case Rep Hematol. 2024 Feb 24
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Breast Cancer Res. 2024 Feb 26;26(1):32. doi: 10.1186/s13058-024-01782-0. Erratum in: Breast Cancer Res. 2024 Mar 13;26(1):46. doi: 10.1186/s13058-024-01805-w.
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
Nat Med. 2023 Jan;29(1):158-169. doi: 10.1038/s41591-022-02113-6. Epub 2023 Jan 9.
Molecular map of chronic lymphocytic leukemia and its impact on outcome
Nat Genet. 2022 Nov;54(11):1664-1674. doi: 10.1038/s41588-022-01140-w. Epub 2022 Aug 4.
ROR1: an orphan becomes apparent
Blood. 2022 Oct 6;140(14):1583-1591. doi: 10.1182/blood.2021014760.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood. 2022 Aug 25;140(8):839-850. doi: 10.1182/blood.2021015014.
Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia.
Frontiers in oncology, 12, 897280. https://doi.org/10.3389/fonc.2022.897280
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Blood. 2022 Jun 2;139(22):3278-3289. doi: 10.1182/blood.2021014488
High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
Leukemia. 2022 Jun;36(6):1609-1618. doi: 10.1038/s41375-022-01543-y. Epub 2022 Apr 13. PMID: 35418613; PMCID: PMC9162914.
Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia.
Cancers (Basel). 2022 Mar 28;14(7):1715. doi: 10.3390/cancers14071715.
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13.
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
J Clin Oncol. 2021 Dec 1;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 7.
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Blood. 2021 Oct 26:blood.2021011895. doi: 10.1182/blood.2021011895. Online ahead of print.
Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia
Cancer Res. 2021 Oct 22:canres.CAN-21-1273-A.2021. doi: 10.1158/0008-5472.CAN-21-1273. Online ahead of print.
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
Blood. 2021 Sep 9;138(10):836-846. doi: 10.1182/blood.2020009578.
Exploring the pathways to chronic lymphocytic leukemia
Blood. 2021 Sep 9;138(10):827-835. doi: 10.1182/blood.2020010029.
Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
Clin Cancer Res. 2021 Sep 1;27(17):4690-4695. doi: 10.1158/1078-0432.CCR-20-4842. Epub 2021 Jun 3.
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Haematologica. 2021 Sep 1;106(9):2364-2373. doi: 10.3324/haematol.2020.272500.
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans
Leukemia. 2021 Jul 20. doi: 10.1038/s41375-021-01344-9. Online ahead of print.
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia
Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536.
Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History
Cancer Discov. 2021 Jun 10:10.1158/2159-8290.CD-21-0276. doi: 10.1158/2159-8290.CD-21-0276. Online ahead of print.
Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism
Leukemia. 2021 Jun;35(6):1621-1630. doi: 10.1038/s41375-020-01055-7. Epub 2020 Oct 23.
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors
Blood. 2021 May 6;137(18):2481-2494. doi: 10.1182/blood.2020005627.
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation
Cancer Cell. 2021 Mar 8;39(3):380-393.e8. doi: 10.1016/j.ccell.2021.02.003.
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia
Leuk Res. 2021 Mar;102:106520. doi: 10.1016/j.leukres.2021.106520. Epub 2021 Feb 5.
Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
J Hematol Oncol. 2021 Jan 15;14(1):17. doi: 10.1186/s13045-021-01032-2.
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy
Blood Cancer Discov. 2021 Jan;2(1):54-69. doi: 10.1158/2643-3230.BCD-19-0058. Epub 2020 Dec 3.
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
J Clin Oncol. 2020 Dec 1;38(34):4042-4054. doi: 10.1200/JCO.20.00948. Epub 2020 Sep 28.
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia
Leuk Res. 2020 Oct;97:106432. doi: 10.1016/j.leukres.2020.106432. Epub 2020 Aug 11.
Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect
Sci Transl Med. 2020 Sep 16;12(561):eabb7661. doi: 10.1126/scitranslmed.abb7661.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.
NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia
Cell Death Differ. 2020 Jul;27(7):2206-2216. doi: 10.1038/s41418-020-0496-1. Epub 2020 Jan 28.
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Haematologica. 2020 Apr;105(4):e164-e168. doi: 10.3324/haematol.2019.223743. Epub 2019 Aug 14.
Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis
Oncogene. 2020 Mar;39(12):2550-2567. doi: 10.1038/s41388-020-1165-z. Epub 2020 Jan 29.
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Leukemia. 2020 Mar;34(3):787-798. doi: 10.1038/s41375-019-0602-x. Epub 2019 Oct 18.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2020 Feb;18(2):185-217. doi: 10.6004/jnccn.2020.0006.
Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels
Haematologica. 2020 Jan;105(1):e22-e25. doi: 10.3324/haematol.2018.212597. Epub 2019 May 2.